Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$4.24 ▼ -0.11
(-2.53%)
MKT CAP: $2.53B • VOL: 20.96M
52W L $3 52W H $6
RXRX // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $74.7M | $58.8M | $44.6M |
| YoY Revenue Growth % | +26.9% | +32.0% | — |
| Gross Profit | $3.7M | $13.6M | $19.6M |
| Gross Margin % | 5.0% | 23.1% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$648.1M | -$479.0M | -$350.1M |
| Operating Margin % | -867.9% | -814.1% | -785.3% |
| Net Income (GAAP) | -$644.8M | -$463.7M | -$328.1M |
| EBITDA (Normalized) | -$643.0M | -$468.0M | -$348.5M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$371.8M | -$359.2M | -$287.8M |
| Capital Expenditures (CapEx) | $6.5M | $13.7M | $2.0M |
| Free Cash Flow (FCF) | -$378.3M | -$372.9M | -$289.8M |
| FCF Margin % | -506.5% | -633.7% | -650.1% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -32.9% |
| Cash & Short-Term Equivalents | $743.3M | $594.4M | $153.1M |
| Total Debt (Short + Long Term) | $154.5M | $186.2M | $325.7M |
| Total Stockholders' Equity | $1.13B | $1.03B | $668.1M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RXRX.